Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
AssigneeArdea Biosciences, Inc.
InventorsLaszlo R. TREIBER, Irina ZAMANSKY, Jean-Luc GIRARDET
Life of this patent
Estimating the term…
Abstract
Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented.
Claims26
A method for treating or preventing gout, comprising administering an effective amount of a crystalline polymorph of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid:
- characterized by peaks at 10.46, 18.76, and 19.83 °2θ±0.1°2θ.
A method for treating hyperuricemia, comprising administering an effective amount of a crystalline polymorph of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid:
- characterized by peaks at 10.46, 18.76, and 19.83 °2θ±0.1°2θ.
A method for treating or preventing a disease caused by elevated uric acid levels, comprising administering an effective amount of a crystalline polymorph of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid:
- characterized by peaks at 10.46, 18.76, and 19.83 °2θ±0.1°2θ.
A method of treating hyperuricemia, treating or preventing gout, or a treating or preventing a disease caused by elevated uric acid levels, comprising administering an effective amount of a crystalline polymorph of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid:
- characterized by peaks at 10.32, 18.84 and 20.75 °2θ±0.1°2θ.
Dependencies are inferred from the claim text.